PCSA had early results on 2 cohorts (Patients) in their 6422 trials, and essentially are holding off on enrolling the 3rd person while they make a few tweaks to dosing and timelines along with discussions with FDA. The early results are strong and this could...
Some developments on a few positions to update quickly: Working on new ideas for the portfolio, the Biotech I noted has ran up about 33% and I am watching now instead of putting out the report. Prefer a better entry, may or may not get it...
DEFTF 2.42- 3.50 Wave 3 near term possible Written up on October 12th at 1.66 a share, now 2.42 up 50% already. I have continued to buy the shares almost daily since the day of the report at really any price. I spoke with CEO Russell Starr...
RESAAS- .65 cents Im long at $1 avg This is at 45 million market cap and I can make a case for 100 million in revenue in next 12-15 months run rate anyways. Its cheap, but lacking progress on partnerships or at least news and also need...
Time for some quick updates, will complete those missing late in week Markets are a little stretched short term as the 3rd wave up in SP 500 is about 25 points above my expectations, but further out I remain bullish to 5500 on SP 500 for...
Some updates on positions, make sure to follow yahoo finance or other websites for press releases on all positions as well. I am looking to add another Biotech near term possibly after lengthy research and discussions with the Chairman of the board who recent invested a...
Some quick updates on a few positions: DEFTF- 1.76 Already moving up from the report price at 1.64. I continue to buy and I will be buying more this morning as well up to 1.80 area. The chart is close to a breakout to $2 resistance I...
PCSA up 10% pre market to 8.70 as of now as the FDA has given them the green light to push into Phase 2a Trial for a constipation indication, a 1.6 Billion market opportunity. We also should look forward to 6422 data within a few...
The micro caps continue to get hit, we are in the October ugly window which typically bottoms the market out seasonally. Liquidity is a problem short term and Mercury is in Retrograde until October 18th adding more fuel to the volatility. My suggestion is we close...
Terren Peizer, Chairman and largest shareholder of EVMO was on a call today with investors and Dave Gentry of Red Chip Review to give corporate updates Obviously the stock has suffered of late along with many micro-caps but I remain bullish on the business model and...
indian xxnx horny desi indian cheating slime wife show boobs in webcam.
